Best Life Sciences Companies in Baden-wurttemberg, Germany
The 84 best Life Sciences companies in Baden-wurttemberg, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novaliq.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Baden-wurttemberg
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Novaliq Developer of reformulation of drug for ocular therapeutics | $115M | 92 mo ago | 30 | Christian Roesky Chief Executive Officer / Managing Director | Series C | 670 patents Ophthalmic drug formulations and delivery systems for dry eye, uveitis, and neovascular diseases | — |
| 2 | Affimed Therapeutics Developer of antibody therapeutic solutions for cancer treatment | $90M | 137 mo ago | 197 | Adi Hoess CEO | Public | 56 patents Engineered multivalent antibody fragments targeting CD16 and EGFRvIII for immune cell engagement | — |
| 3 | Cellzome Small-molecule kinase targeted drugs to treat inflammatory diseases | $78M | 210 mo ago | 90 | — | Acquired | 202 patents Enzyme‑focused drug discovery: modulators/inhibitors of gamma‑secretase, PI3K, tankyrase. | — |
| 4 | Apogenix Developer of novel protein therapeutics for the treatment of cancer and inflammatory diseases | $72M | 54 mo ago | 57 | — | Series B | 369 patents Engineered multi-specific protein agonists for immune checkpoint modulation and cancer therapy | — |
| 5 | Molecular Health Genomic software solutions for healthcare providers | $27M | 127 mo ago | 121 121 → 66 (-45%) | Friedrich Bohlen Founder & CEO | Late Stage | 59 patents Computational genomics and clinical decision-support platforms for adverse event and cancer analysis | — |
| 6 | Luxendo Manufacturer of light-sheet fluorescence microscopes for 3D bioimaging | $8M | 113 mo ago | 20 20 → 14 (-30%) | — | Acquired | — | 1 award |
| 7 | Epignostix Developer of DNA methylation-based therapeutics for tumor classification | $5M | 23 mo ago | — | Daniel Schrimpf Co-Founder | Seed | — | — |
| 8 | faCellitate Developer of synthetic coatings and surface technologies for cell culture applications | $4M | 45 mo ago | 50 | Simon Widmaier Co-Founder & Managing Director | Seed | 13 patents Cell‑culture surface coating polymers and biocompatible device attachment technologies | 1 partnership |
| 9 | VERAXA Developer of antibody therapeutics for cancer treatment | $3M | 83 mo ago | 36 | Edward A. Lemke Co-Founder | Series B | — | 1 partnership |
| 10 | Precisis Portfolio of devices and tools for neurological surgery | $3M | 48 mo ago | 14 | — | Funding Raised | 82 patents Implantable neurostimulation electrodes and lead connectors for seizure and neural therapy | — |
| 11 | Thericon Developer of image diagnostic device for the diagnosis of bladder cancer | $3M | 48 mo ago | — | Nikolaos Deliolanis Co-Founder & CEO | Funding Raised | — | — |
| 12 | Vibrosonic Developer of hearing solutions | $2M | 32 mo ago | 22 22 → 35 (+59%) | Jonathan Schachtele Co-Founder & CTO | Series B | 42 patents Implantable electroacoustic transducers and adaptable ear‑drum modules for hearing restoration | — |
| 13 | Meidrix Developer of collagen-based implants for soft tissue regeneration | $1M | 180 mo ago | 10 10 → 8 (-20%) | Michaela Noll CEO | Series A | — | — |
| 14 | stimOS Developer of surface functionalization technologies and biosimilar implant systems for manufacturers | $839K | 70 mo ago | 5 | — | Series A | 14 patents Biomaterials and manufacturing processes for dental and bone implant devices | — |
| 15 | Sciomics Enabling Precision Medicine through Advanced Protein Biomarkers | $719K | 102 mo ago | — | Christoph Schroeder Founder & CEO | Funding Raised | 8 patents Predictive molecular diagnostics for COVID-19 severity and acute kidney injury risk assessment | — |
| 16 | Arthro Kinetics Implants for regenerative medicine and musculoskeletal system | $690K | 210 mo ago | 45 | — | Series A | 13 patents Collagen biomatrix production for tissue engineering and spinal disc annulus closure devices | — |
| 17 | PEPperPRINT Provides the peptide microarray platform | $676K | 70 mo ago | 29 29 → 30 (+3%) | — | Seed | 12 patents Patents concentrated in transport & manufacturing processes | 1 launch |
| 18 | Biobyte solutions Provider of customized bioinformatics tools and consulting services | $606K | 89 mo ago | — | Ivica Letunic CEO | Funding Raised | — | — |
| 19 | Voxalytic Developer of NMR probes and microcoil sensors for spectroscopy applications | $293K | 81 mo ago | — | Ulrike Wallrabe Founder | Funding Raised | 5 patents Patents concentrated in computing, sensing & instrumentation | — |
| 20 | Lumobiotics Photoswitchable peptides for pancreatic cancer and prosthetic joint infections | $199K | 63 mo ago | — | Leo St Founder & COO | Funding Raised | — | — |
Top 12 Life Sciences companies in Baden-wurttemberg
#1
Seed · Heidelberg, Baden-wurttemberg · founded 2022$4.6Mraised▾
Developer of DNA methylation-based therapeutics for tumor classification. It revolutionize tumor classification by harnessing the power of methylation-based models to improve diagnosis, prognosis, and treatment decisions.
- Jul 2024Seed$4.6M
#2
Series B · Heidelberg, Baden-wurttemberg · founded 2005 · 57 employees$72.3Mraised▾
Developer of novel protein therapeutics for the treatment of cancer and inflammatory diseases. The compound´s mechanism of action is either based on the targeted modulation of the programmed cell death or on the inhibition of tumour cell growth. The lead product is APG101 (fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG antibody) is being developed for the treatment of Glioblastoma multiforme and myelodysplastic syndrome.
- Dec 2021Series B$29.4M
- Apr 2008Series B$42.9M
#3
Series B · Mannheim, Baden-wurttemberg · founded 2016 · 22 employees$2.2Mraised▾
Vibrosonic develops hearing solutions for hearing impaired individuals. The company has developed vibrosonic actuator which is an externally invisible piezoelectric microspeaker. It offers high amplification of sound which enables hearing-impaired users to hear sound. The company is a spin-off of the Fraunhofer Project Group for Automation in Medicine and Biotechnology.
- Oct 2023Series B—
- Feb 2021Grant (prize money)$60.3K
- Mar 2019Grant (prize money)$2.1M
#4
Series C · Heidelberg, Baden-wurttemberg · founded 2007 · 30 employees$115Mraised▾
Novaliq is developing reformulated drug products based on semi-fluorinated alkanesfor ocuar therapeutics. Its proprietary platform uses semi-fluorinated alkanes as a delivery alternative to water, and drug carriers being perfluorohexyloctane and perfluorobutylpentane. The company has an approved OTC product called NovaTears to cure a mild dry eye. In addition, the company has another compound called CyclASol for a severe dry eye which in phase 3 trials. Its a non-aqueous and preservative-free formulation containing cyclosporine.
- Oct 2018Series C$53M
- Jan 2016Grant (prize money)$162.1K
- Apr 2013Series B$18.1M
- May 2012Series A$5.1M
#5
Public · Heidelberg, Baden-wurttemberg · founded 2000 · 197 employees$89.7Mraised▾
Developer of antibody therapeutic solutions for cancer treatment. It is a biopharmaceutical company, engages in the discovery and development of recombinant antibody therapeutics for the treatment of cancer and other diseases. It offers a tetravalent antibody that is targeting tumor cells. The company also provides programs for the treatment of Non-Hodgkin's Lymphoma, Hodgkin's diseases, thrombosis and autoimmune, leukemia, myeloma, solid tumors, metastasis, non-cancer indications, allergy, and asthma diseases.
- Jan 2015Grant (prize money)$3M
- Oct 2012Series D$20.1M
- Apr 2010Series C$26.4M
- Feb 2008Series B$7.4M
#6
Acquired · Heidelberg, Baden-wurttemberg · founded 2000 · 90 employees$78.1Mraised▾
Cellzome is a drug discovery company focussed on developing a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline small-molecule therapeutics is based on Kinobeads, a proprietary technology for screening and profiling kinases in relevant cells and tissues. Its small molecules target inflammatory mediators such as PI3Kg and Zap-70, Jak3 and mTOR and have a potential to be oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma. It was acquired by GSK for $99M in May 2012.
- Dec 2008Grant (prize money)$4.9M
- Mar 2003Series C$47.1M
- Mar 2001Series B$31M
#7
Seed · Mannheim, Baden-wurttemberg · founded 2019 · 50 employees$3.7Mraised▾
Developer of synthetic coatings and surface technologies for cell culture applications. The company provides polymeric coatings that modify surfaces without chemical reactions. Its inert layers prevent non-specific interactions of proteins and cells. The company offers products for three-dimensional cell culture, drug discovery, toxicology, and stem cell research.
- Sep 2022Seed$3.7M
#8
Funding Raised · Heidelberg, Baden-wurttemberg · founded 2002 · 14 employees$2.8Mraised▾
Precisis develops technologies and devices to treat various neurological conditions. The company's products include - Praezis Plus, a stereotactic 3D design software designed for the optimization of neurological surgical procedures; CobraLeaf MLC system that provides the ability to conform Cobalt-60 radiotherapy to the exact tumor shape without the cumbersome use of lead blocks. The company also provides EASEE, a minimally invasive brain stimulation system placed directly under the scalp for the treatment of epilepsy. In addition, the company offers surgical tools and radiation protection systems for neurosurgical brachytherapy, implantation hardware, and collimators. It provides solutions for precision interventions in neurosurgery, radiotherapy, and stereotaxy; and Parkinson's and tumors.
- 2022Grant (prize money)$2.8M
#9
Funding Raised · Mannheim, Baden-wurttemberg · founded 2019$2.7Mraised▾
Therion develops image diagnostic device for the diagnosis of bladder cancer. The rMSI technology offers a feature to differentiate optically whether tissue is malignant or healthy. It provides a white light image with vascular contrast and photodynamic diagnosis in one image and offers identification of lesions.
- Jun 2022Grant (prize money)$2.7M
#10
Late Stage · Heidelberg, Baden-wurttemberg · founded 2004 · 121 employees$26.9Mraised▾
Genomic software solutions for healthcare providers. Its proprietary Dataome platform is a SaaS product and is capable of converting both structured and unstructured NGS data into clinically actionable results. The Dataome Knowledgebase contains information for 97k drugs, 54M drug names, 4.6M drug interactions, 85k genomic variants, and 109k clinical trials. Currently, Molecular Health has three products based on its technology. MH Guide Labs converts genetic variant data into a comprehensive tumor profile to enable labs with NGS capabilities. MH Guide Hospitals is an enterprise solution that uses sequencing data to evaluate drug efficacy, drug-drug interactions, and drug-patient compatibility for tailored cancer therapies. MH Effect is a specialized product that predicts drug-drug interactions and drug-induced adverse effects by using patient genomic data.
- Nov 2015PE$26.9M
#11
Acquired · Heidelberg, Baden-wurttemberg · founded 2015 · 20 employees$8.4Mraised▾
Manufacturer of light-sheet fluorescence microscopes for 3D bioimaging. These microscopes enable fast, high-resolution imaging of live or cleared tissue samples, avoiding phototoxicity. The company offers various models suited for diverse applications, including imaging of cleared samples, live samples, organoids, and embryos. Supporting software integrates microscopy control, image viewing, and post-processing. Additional modules enhance functionality, offering photomanipulation, environmental control, and improved image quality. The company also provides resources such as FAQs, educational materials, and webinars to support researchers.
- Jan 2017Series A$8.4M
- 2015Seed—
#12
Series B · Heidelberg, Baden-wurttemberg · founded 2017 · 36 employees$3.4Mraised▾
Developer of antibody therapeutics for cancer treatment. The company is focusing on ADC engineering and functional antibody screening for the treatment of oncological conditions. The company’s droplet-based microfluidic screening technology and its innovative antibody and protein conjugation technology allow for a rapid generation of antibodies against the most complex target molecules.
- Jun 2019Series B$3.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Germany
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,297 Germany-affiliated papers.
- Heidelberg University85
- German Cancer Research Center49
- Ludwig-Maximilians-Universität München48
- Technical University of Munich43
- Karlsruhe Institute of Technology33
- Gene3→29
- Mutant3→19
- Transcription (linguistics)3→16
- Messenger RNA1→14
- Immune system1→12
- Gene3→20
- Agriculture2→12
- Extracellular1→11
- Immune system1→11
- Transcriptome1→9
- Antibiotic resistance2→9
- Gene1→7
- Agriculture4→9
- Antimicrobial1→4
- Microbiome1→4
Where biotechnology is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in Germany
Germany biotechnology patent filing is cooling — 53,233 filings from 8,000 assignees (2016–2025), led by Immatics Biotechnologies, BASF Plant Science, BASF SE; annual filings 4819→4267.
- Immatics Biotechnologies4872
- BASF Plant Science3982
- BASF SE3543
- Boehringer Ingelheim INT3438
- Merck Patent3133
- MAX Planck Gesellschaft1799
- Evonik Degussa1680
- Amgen RES Munich1665
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.